AKL Technologies Ltd
"Clinic-to-lab" model: synthetic drug candidates are developed from established natural products.where safety & efficacy is established
AKL is developing APPA to address a major unmet need in treating osteoarthritis. Originally naturally derived, APPA is now a fully synthetic drug that has shown encouraging results in controlled animal studies and has favourable anecdotal observations in animal and human subjects. AKL’s “clinic-to-lab” model provides rare insights into drug performance before embarking on conventional development, leading to a significant reduction in risk.